RxDoctor Payments Data

Darshak Karia, MD

Advanced Heart Failure and Transplant Cardiology · Augusta, GANPI 1033170097

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $182,680 of the $296,031 with a category attached, or 61.7%. 20 manufacturers reported payments, led by Merck at 48.7% of the total. Reporting peaked in 2022 at $117,056 and has fallen 85.3% since, to $17,155 in 2025. Among advanced heart failure and transplant cardiology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$296,031in general payments, 2019–2025

Across 487 payments — averaging $607.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$144K
  • Abbott$53K
  • AstraZeneca$38K
  • Boehringer Ingelheim$21K
  • Alnylam Pharmaceuticals Inc.$16K
  • Novartis$11K
  • plus $13K from 14 others
$611,545in research payments, 2019–2025

Across 100 payments — averaging $6115.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$294K
  • Boston Scientific$160K
  • Novartis$82K
  • Procyrion, Inc.$45K
  • AstraZeneca$31K

What the payments were for

  • Consulting fees$39,63813%
  • Speaking & faculty fees$182,68062%
  • Travel & lodging$60,91221%
  • Food & beverage$12,6824%
  • Education$1190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$296,031 in reported general payments places this provider in the 90th percentile of 40 advanced heart failure and transplant cardiology providers in Georgia.

See all advanced heart failure and transplant cardiology providers in Georgia

Medicare billing

Part B allowed, 2024
$134,952
Medicare patients
253
Services billed
1,602

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UptraviSelexipag140$3,098,461
VyndamaxTafamidis31$710,081
EntrestoSacubitril/Valsartan465$483,243
JardianceEmpagliflozin336$331,354
AdempasRiociguat19$267,666
EliquisApixaban229$218,371
FarxigaDapagliflozin Propanediol235$214,025
VerquvoVericiguat46$52,799
Sildenafil Citrate80$11,703
OzempicSemaglutide11$10,807
Midodrine Hcl119$8,792
Metoprolol Succinate492$5,809
Hydralazine Hcl295$3,883
Isosorbide Mononitrate ErIsosorbide Mononitrate222$3,015
Amiodarone Hcl129$2,986

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Uptravi$4,676$3,098,461140 claims
PfizerVyndamax, Eliquis$65$928,452260 claims
NovartisEntresto$11,385$483,243465 claims
Boehringer IngelheimJardiance$21,014$331,354336 claims
AstraZenecaFarxiga$37,523$214,025235 claims
MerckVerquvo$144,141$52,79946 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 40 advanced heart failure and transplant cardiology providers in Georgia.

Other advanced heart failure and transplant cardiology in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →